AZURITY PHARMACEUTICALS, INC. ANNOUNCES FDA APPROVAL OF MYHIBBIN™ (mycophenolate mofetil oral suspension)

WOBURN, Mass., May 6, 2024 /PRNewswire/ — Azurity Pharmaceuticals, a pharmaceutical company focused on developing innovative dose forms and formulations of products to serve the needs of overlooked patients, announced today that the U.S. Food and Drug Administration (FDA) has approved…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.